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BCL-2 family proteins are integral com-
ponents of a genetically defined, evolu-
tionarily conserved apoptosis pathway
(Adams and Cory, 1998). Defective con-
trol of this pathway, leading to the sup-
pression of apoptosis, is a hallmark of
cancer (Green and Evan, 2002) and is
linked in some cases to the deregulation
of BCL-2 family members. Members of
this family are characterized by the pres-
ence of up to four distinct segments of
amino acid homology, termed BCL-2
homology (BH) domains. The multi-BH
domain family members operate to either
suppress apoptosis (e.g., BCL-2, BCL-
XL) or promote apoptosis (e.g., BAX,
BAK), whereas the BH3-only subfamily
members identified to date (e.g., BAD,
BID) function exclusively to promote cell
death. As their name implies, BH3-only
proteins share the BH3 domain but
appear otherwise unrelated. Structure/
function studies revealed that BH3
domains function as uniquely important
“death domains” in these proteins, essen-
tial for both their proapoptotic activity
and, not coincidently, for their ability to
bind to multidomain BCL-2 family mem-
bers (Bouillet and Strasser, 2002).
A convergence of genetic and bio-
chemical studies has established that
BH3-only proteins act at an upstream
point in an apoptotic signal-transduction
cascade that leads ultimately to cyto-
chrome c release from mitochondria and
activation of caspases. BH3-only pro-
teins, of which there are at least eight in
mammalian cells, serve to integrate
diverse apoptotic stimuli into a common
cell death pathway governed by BCL-2
and its multi-BH domain relatives
(Bouillet and Strasser, 2002). A remark-
able number of seemingly unrelated cell
death stimuli—including ligation of Fas
and related TNF family receptors, depri-
vation of growth factors, DNA damage,
and loss of cell matrix attachment—have
all been linked to the activation of specific
BH3-only family members through a vari-
ety of transcriptional and posttranslation-
al mechanisms. Nevertheless, a common
theme has emerged from the analysis of
multiple BH3-only proteins: the BH3
domain is “unleashed” in response to a
cell death stimulus and initiates mito-
chondrial events associated with apopto-
sis by targeting mitochondrial-localized
multidomain BCL-2 family members.
The mechanism by which BH3
domains deliver their deadly signal has
been elucidated by the analysis of genet-
ically modified mice, together with in vitro
assays which probed the function of
BCL-2 family members in isolated mito-
chondria. The two multidomain proapo-
ptotic proteins, BAK and BAX, serve as
essential effectors of the mitochondrial
apoptotic pathway and are necessary
for induction of cell death by BH3-only
proteins (Wei et al., 2001).The BH3-only
protein, BID, binds (via its BH3 domain)
and activates both BAK and BAX, trig-
gering the oligomerization of these pro-
teins in mitochondrial membranes and
the subsequent release of cytochrome c
into the cytoplasm (Wei et al., 2000).
BID also interacts with multiple antiapo-
ptotic BCL-2 family members, including
BCL-2, BCL-XL, and Bfl-1/A1 (Wei et al.,
2000; Werner et al., 2002). These anti-
apoptotic proteins, by contrast to the
direct effector role ascribed to BAK and
BAX, appear to function principally as
regulators, sequestering BH3-only pro-
teins and thus preventing activation of
BAK and BAX (Cheng et al., 2001).
Certain BH3-only proteins display
selective binding to specific BCL-2 family
members. For example, BID binds to both
pro- and antiapoptotic BCL-2-related pro-
teins, whereas BAD binds only antiapo-
ptotic proteins such as BCL-2 and BCL-
XL. In this issue of Cancer Cell, Letai et al.
(2002) report that the binding selectivity
and distinct functional activity of BH3-
only proteins are recapitulated in the con-
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Recent studies have clarified how the BH3 domain, a short peptide motif found in certain BCL-2 family proteins, triggers
key mitochondrial events associated with apoptosis.
Figure 1. A model for the control of apoptosis
by BH3 domain-only proteins 
Cell death signals can engage two distinct
classes of BH3-only proteins, BID-like activa-
tors and BAD-like enablers. BID-like pro-
teins directly bind and activate mitochondri-
al-localized BAK and BAX (1), triggering
BAK/BAX oligomerization and apoptosis (2).
Antiapoptotic BCL-2 proteins sequester BID-
like proteins, preventing their interaction with
BAK/BAX (3). BAD-like proteins sensitize or
enable apoptosis by binding antiapoptotic
BCL-2 family proteins, and thus preventing
the sequestration of BID-like BH3 activators
(4). Overexpression of BCL-2 or related pro-
teins in cancer cells may sequester both
classes of BH3-only proteins and thereby
block cell death (5). (Figure after Letai et al.,
2002.)
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text of isolated, synthetic BH3 peptides.
Integrating these results with previous
studies, Letai et al. propose a revised
“rheostat” model (Figure 1) that repre-
sents a significant makeover from earlier
versions that focused principally on the
interaction of BCL-2 and BAX. Although it
is likely to be vastly oversimplified, the
model explains how the interplay
amongst BH3-only proteins and multido-
main BCL-2 family members regulate cell
death (Letai et al., 2002). BAK and 
BAX function as mitochondrial-localized
receptors for the “activator” or agonist
class of BH3 peptide ligands, typified by
the BID BH3 domain. Upon binding,
these BID-like BH3 ligands trigger the
oligomerization and activation of BAK
and BAX receptors via an unknown
mechanism.This key proapoptotic signal-
ing event can be blocked by sequestra-
tion of BID-like BH3 ligands by BCL-2/
BCL-XL and related antiapoptotic mul-
tidomain proteins, which function essen-
tially as decoy receptors in this model. A
distinct functional class of BH3 ligands,
typified by BAD and BIK BH3 peptides,
do not bind and activate BAK/BAX recep-
tors directly, but instead promote apopto-
sis indirectly by binding and neutralizing
BCL-2/BCL-XL decoy receptors. Pre-
sumably, this increases the effective
activity of BID-like BH3 ligands by inhibit-
ing their sequestration by BCL-2/BCL-XL.
Two distinct functional classes of
BH3 domains have, therefore, been
defined by these studies. Using the termi-
nology of Letai et al., BID-like BH3
domains “activate” apoptosis, through
direct targeting of BAK/BAX, whereas
BAD-like BH3 domains “sensitize” or
enable apoptosis, by neutralizing BCL-2
and related antiapoptotic proteins. The
BH3-only protein BIM appears to provide
a second example of a BID-like BH3
domain, based on the ability of an isolat-
ed BIM BH3 peptide to activate BAX (and
to a lesser degree BAK) and trigger
cytochrome c release (Letai et al., 2002).
This was unexpected since full-length
BIM (BIML) does not show appreciable
affinity for BAK or BAX and does not
induce cytochrome c release in in 
vitro assays (Terradillos et al., 2002).
Apparently, the presentation of the BIM
BH3 domain is somehow masked in the
context of BIML, since naturally occurring
truncated isoforms of BIM, BIMS, and
BIMAD bind to BAX and trigger its acti-
vated conformation (Marani et al., 2002).
The selectivities of other known BH3-only
proteins remain to be carefully examined
in light of these findings. It will also be
interesting to determine whether the prin-
ciple of distinct BH3 domain activities
applies to nonmammalian systems,
including the C. elegans BH3-only protein
EGL-1, and in Drosophila cell death path-
ways, where BH3 proteins have not yet
been identified. Moreover, the ability of
BAD-like BH3 domains to bind exclusive-
ly to antiapoptotic BCL-2 family members
raises the possibility that BH3-only pro-
teins with the inverse selectivity might
exist: BID-like BH3 activators that bind
exclusively to BAK/BAX. Such proteins
would be predicted to be especially pow-
erful inducers of apoptosis, immune from
sequestration by BCL-2. BH3-only “acti-
vator” proteins in this class, if they exist,
would not have been identified in BCL-2-
interaction screening approaches used to
identify most of the known BH3-only fam-
ily members.
Understanding the functional intrica-
cies of BH3 domains may ultimately pay
off in efforts to develop novel anticancer
agents that engage the apoptosis path-
way selectively in tumor cells. In principle,
cytotoxic insults that induce apoptosis
through activation of BID-like BH3-only
proteins are inherently different from
stimuli that promote apoptosis through
the activation of BAD-like BH3-only pro-
teins. The latter, for example, may be
insufficient to trigger cell death unless
there are adequate levels of activated
BID-like BH3 molecules provided by a
separate apoptotic stimulus. Letai et al.
provide initial experimental support for
this scenario by examining the proapo-
ptotic effects of cell-permeable BH3 pep-
tides in a tumor cell line. A BID-BH3 pep-
tide proved to be an effective inducer of
apoptosis, and importantly, this activity
depended on an intact BH3 domain and
the function of endogenous BAK/BAX. By
contrast, a BAD-BH3 peptide was not
toxic to cells at the concentrations tested,
but significantly enhanced the ability of
the BID-BH3 peptide to induce apoptosis
at otherwise sublethal concentrations.
From the perspective of cancer drug
development, agents that mimic the
activity of a BAD-like BH3 domain might
have a useful therapeutic window, sensi-
tizing tumor cells to intrinsic or extrinsic
apoptotic stimuli (e.g., activated onco-
genes and chemotherapeutic drugs,
respectively). In a much broader view,
suppression of apoptosis has been impli-
cated as a critical, if not essential, event
for the development of cancer (Green
and Evan, 2002). Unfortunately, the
mechanisms that frequently block cell
death in tumor cells, particularly in solid
cancers, remain poorly defined. It should
now be possible to exploit model BAD-
like and BID-like BH3 peptides as
research tools to help address the long-
standing, important question of the pre-
cise contribution of BCL-2 family proteins
to the survival of human tumor cells.
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